Featured Post from Georgia Tech College of Engineering

CRISPR is the genetic game changer – but are we ready?

Dec 10, 2019

2 min

Michael Davis

CRISPR is here to stay – and the daily advances of this technology and stem cell therapy seem to be moving at a near exponential speed.



“CRISPR Therapeutics of Zug, Switzerland, reported that one patient with sickle cell anemia and another with beta thalassemia appear to have benefited from the same CRISPR-based intervention for up to 9 months, STAT reports. (The company gave STAT an early look at the data but did not allow outside commenters to see the results.) Before the treatment, both patients required multiple infusions each year of red blood cells. CRISPR Therapeutics, collaborating with Vertex Pharmaceuticals, removed blood stem cells from their bodies and modified them with CRISPR to knock out a gene that shuts down production of fetal hemoglobin. When the edited cells were put back in each patient’s body through a stem cell transplant—which required a toxic chemotherapy to kill their own stem cells—both people produced high levels of fetal hemoglobin and no longer needed transfusions.” November 19 – Science Mag




CRISPR and how it will shape the future of genetics, health care and society are the subject of great debate, hope and concern and if you are a journalist covering this topic and need an expert source for insight and perspective – let us help.



Dr. Michael Davis researches cardiac regeneration, stem cell therapy and preservation at the Georgia Tech College of Engineering where he also is the Associate Chair for Graduate Studies in Biomedical Engineering. Michael is available to speak to media regarding this topic, simply click on his icon to arrange an interview.


Connect with:
Michael Davis

Michael Davis

Professor, Associate Chair for Graduate Studies, Biomedical Engineering

Michael Davis researches cardiac regeneration and preservation.

Stem Cell TherapyCardiac Regeneration

You might also like...

Check out some other posts from Georgia Tech College of Engineering

2 min

It’s all eyes on Africa as the UN looks to find ways to ensure universal health care for all

It was a historic moment earlier this month as the United Nations and African Union pledged to pursue bolds goals that will strengthen global health and provide health care to all across Africa. “The Memorandum of Understanding we have signed today is an important step towards formalizing the cooperation between WHO and the African Union and to implementing the Addis Ababa Call to Action,” said the WHO chief. “The Addis Ababa Call to Action is a powerful commitment from African Union leaders to increase domestic financing for health, and to hold themselves accountable for that commitment”, he added. Following a political declaration on universal health coverage, which was approved in September by all UN Member States, the General Assembly adopted a global resolution to translate that commitment into reality by legislators in 140 countries. November 18 - UN News It’s indeed a bold declaration and one that will require prevention, infection control and affordable delivery of care. Key UN-AU collaboration specifics Provide technical expertise to the African Medicines Agency and create an environment to foster local production of medicines. Strengthen collaboration between WHO and the Africa Centers for Disease Control and Prevention – with a particular focus on emergency preparedness, to build defenses against epidemics and other health emergencies. Support the implementation of the Addis Ababa Call to Action on universal health coverage and the AU Declaration on Domestic Financing. The prospects are positive, but delivery will be a challenge, and if you are a journalist covering this topic and need an expert source for insight and perspective – let us help. Dr. Saad Bhamla is an Assistant Professor of Chemical & Biomolecular Engineering at the Georgia Tech College of Engineering where he also runs the Bhamla Lab that develops low cost tools for science education and global health.  Saad is available to speak to media regarding this topic, simply click on his icon to arrange an interview.

2 min

Locking down your data. Are lawmakers finally waking up to the importance of privacy?

Data collection and data control are becoming international issues. As the lucrative and important pieces of customer data collection become a priority for major tech and software companies – privacy and protection is now emerging as the key issue for international legislators. Just recently, Microsoft had to update several of its agreements with cloud customers and re-classify its role in Europe. Last month, as part of an enquiry that opened earlier this year, the European Data Protection Supervisor (EDPS) expressed 'serious concerns' over whether the relevant contractual terms were compliant with GDPR, and over Microsoft's role as a data processor or data controller for EU institutions. The report followed the publication of a series of papers by the Dutch Ministry of Justice and Security, suggesting that Office 365 was breaching GDPR by collecting 'functional and diagnostics data', including email subject lines and text run through a spell-checker. Microsoft has now acknowledged its position as a data controller - which has a higher bar for ensuring user data - when it comes to the provision of enterprise services. "In the [Online Services Terms] OST update, we will clarify that Microsoft assumes the role of data controller when we process data for specified administrative and operational purposes incident to providing the cloud services covered by this contractual framework, such as Azure, Office 365, Dynamics and Intune," says Julie Brill, Microsoft's corporate vice president for global privacy and regulatory affairs and chief privacy officer. "This subset of data processing serves administrative or operational purposes such as account management; financial reporting; combating cyber attacks on any Microsoft product or service; and complying with our legal obligations."  Forbes Magazine – November 18 Data collection and control are becoming big issues on a global scale as more and more governments are looking for consumer protection while companies are seeking the profit that comes from the information customers provide voluntarily and sometimes unwillingly . Are you a reporter covering technology, privacy and data collection and control?  Did you know that there is value in the results of spell-checkers and document review tools? If you have questions or need an expert source for insight and perspective – let us help. Dr. Rachel Cummings is an expert in data privacy, algorithmic economics, optimization, statistics, and information theory. Dr. Cummings is available to speak with media regarding data privacy and other topics, simply click on her icon to arrange an interview.

2 min

Gene therapy and the next frontier of medicine

Genetic testing today is mainstream, marketing to consumers who want to know where in Europe they came from or what types of hereditary diseases they could develop. For around $200 you can trace your family tree to learn your origins or identify genetic abnormalities that could signal disease. James Dahlman, assistant professor in the College of Engineering’s biomedical engineering department, specializes in genetics and believes these genotyping services can be helpful, as long as they are used responsibly. “If you’re going to start making medical predictions, you have to be careful,” said Dahlman. “Most people are not equipped to interpret statistics correctly, which can lead to negative predicting and ethical dilemmas. In a few years, genetic counselors will be in high demand so folks can make better decisions about their health.” Dahlman is fascinated by genetics, citing gene therapy as the most interesting field in the world. And it’s a field that he is revolutionizing through his research. Gene therapy is an experimental technique that uses genes to treat or prevent diseases, including hemophilia, Parkinson’s, cancer and HIV. It can help manage a number of diseases by leveraging genes instead of drugs or surgery. Although gene therapy shows promise, there are still risks involved, including unwanted immune system reactions or the risk of the wrong cells being targeted. That’s where Dahlman’s research comes in. Dahlman’s lab focuses on drug delivery vehicles, which are nanoparticles. The nanoparticle delivers gene therapies to the right place in the body to fight disease. It’s critical that the gene therapies only target the unhealthy cells to avoid damaging healthy ones. Dahlman is laser focused on ensuring the nanoparticles know what paths to take to reach the correct organ to start the healing process. “The issue with genetically-engineered drugs is that they don’t work unless they get to the right cell in the body,” said Dahlman. “You can have the world’s best genetic drug that's going to fix a tumor or eradicate plaque, but it’s not going to be effective unless it travels to the right organ. In my lab, we design different nanoparticles to deliver the genetically-engineered drugs to the correct location.” The field of genetic therapy is fascinating – and if you are a journalist looking to cover this topic or have questions for upcoming stories – let our experts help. James Dahlman is an Assistant Professor in the Georgia Tech BME Department. He is an expert in the area of biomedical engineering and uses molecular biology to rationally design the genetic drugs he delivers. This research is redefining the field of genetic therapy. Dr. Dahlman is available to speak with media – simply click on his icon to arrange an interview.

View all posts
Powered by